CD8A and neoplasm: The CD8+ T cell expansion with neoadjuvant therapy was not observed to the same magnitude with adjuvant therapy, supporting the notion that PD-1 inhibition may enhance and rely on the antitumor T cell response by the primary tumor while it is still in situ.